<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278758</url>
  </required_header>
  <id_info>
    <org_study_id>CASA404A2109</org_study_id>
    <secondary_id>EudraCT 2009-017159-88</secondary_id>
    <nct_id>NCT01278758</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function</brief_title>
  <official_title>A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of ASA404 in
      patients with refractory or relapsed metastatic cancer with impaired renal function and with
      normal renal function. It is very possible that patients with renal impairment will show
      differences in renal excretion of parent ASA404 and its metabolites, warranting a study that
      leads to a better pharmacokinetic assesssment in this population.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pK of a single intravenous dose of ASA404 1200 and 1800 mg/m2 monotherapy in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of a single i.v. dose of ASA 1200 and 1800 mg/m2 +chemotherapy (doctaxel or paclitaxel + carboplatin) in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of ASA404 in adult cancer patients with impaired renal function compared to matching patients with normal renal function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of ASA404 1200 or 1800 mg/m2 in combination with chemotherapy (docetaxel or paclitaxel + carboplatin)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate ASA404 pharmacokinetic parameters including AUC (0-t last),), AUC (0-inf)), T ((Â½)), CL, V(Z), Cmax, and Tmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate renal clearance (CLR) of ASA404.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>ASA404 + standard therpy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA404, DMXAA or DXAA</intervention_name>
    <arm_group_label>ASA404 + standard therpy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having histologically-proven solid tumors, who are either refractory to
             standard chemotherapy;

          -  Patients whom chemotherapy with an investigaional agent in combination with docetaxel,
             or paclitaxel + carboplatin is appropriate;

          -  Creatinine clearance according to Cockcroft-Gault formula : Normal &gt; 80 mL/min, Mild
             50-80 mL/min, Moderate 30-&lt;50 mL/min;

          -  A minimum of 4 weeks must have elapsed since the last treatment with other cancer
             therapies;

          -  Potassium, calcium, magnesium and phosphorus values within the normal range;

          -  Body Mass Index (BMI) must be within the range of 18 and 30

        Exclusion Criteria:

          -  Patients having CNS metastases, must have a CT or MRI of the brain performed to rule
             out CNS metastases;

          -  Patients with leptomeningeal disease metastases;

          -  Radiotherapy &lt;/- weeks prior to starting study drug;

          -  Major surgery &lt;/ 4 weeks prior to the start of study;

          -  Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14
             days prior to starting study drug;

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Investigative Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center, Hematology/Oncology Dept.</name>
      <address>
        <city>Indiannapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology /Oncology Associates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Ford Cancer Center/Clinical Trials Office, Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2011</study_first_submitted>
  <study_first_submitted_qc>January 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or metastatic cancer,</keyword>
  <keyword>refractory,</keyword>
  <keyword>core phase,</keyword>
  <keyword>extension phase,</keyword>
  <keyword>dose escalation,</keyword>
  <keyword>standard chemotherapy,</keyword>
  <keyword>doctaxel,</keyword>
  <keyword>paclitaxel,</keyword>
  <keyword>carboplatin,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

